Amesite Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amesite Inc. on July 13, 2026. The report details the results of the Company's Annual Meeting of Stockholders held on the same date. Amesite Inc. is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "AMST."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance metrics.
Material Changes and Voting Results
On the Record Date of May 22, 2026, there were 5,852,985 shares of common stock issued and outstanding. Approximately 40% of these shares (2,321,797) were represented at the Annual Meeting, constituting a quorum. Stockholders approved four proposals:
- Proposal 1 (Election of Directors): Ann Marie Sastry, Ph.D., and Barbie Brewer were elected as Class II directors for a three-year term.
- Proposal 2 (Auditor Ratification): The appointment of Novogradac & Company LLP as the independent registered public accounting firm for the year ending June 30, 2026, was ratified.
- Proposal 3 (Equity Plan Amendment): Stockholders approved an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for issuance by 1,000,000 and increase the number of shares available for incentive stock options by 1,000,000.
- Proposal 4 (Warrant Exercise): In accordance with Nasdaq Listing Rule 5635(d), stockholders approved the issuance of an aggregate of 1,393,732 shares of common stock upon the exercise of Series A-1 warrants and 1,393,732 shares upon the exercise of Series A-2 warrants.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, outlook, specific risks, or contingencies beyond the standard disclosure of the voting results and the amendment to the equity plan.
Key Facts for Investor Verification
- Verify the impact of the 2,000,000 share increase in the 2018 Equity Incentive Plan on future dilution.
- Confirm the total number of shares to be issued upon the exercise of Series A-1 and A-2 warrants (2,787,464 total shares).
- Review the definitive proxy statement filed on June 3, 2026, for detailed descriptions of the proposals and director biographies.
- Note that approximately 60% of outstanding shares were not represented at the Annual Meeting.